Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Glaucoma innovation: Eight themes to watch in 2026 | Ophthalmology Times
Glaucoma care is evolving through the integration of artificial intelligence, advanced procedures, and personalized treatment strategies. (Image credit: AdobeStock/thodonal) As the ophthalmology community observes Glaucoma Awareness Month this January, glaucoma specialists point to incremental integration of technologies that support earlier…
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab | Ophthalmology Times
(Image Credit: Adobe Stock/fotofabrika) Ollin Biosciences has announced positive topline results from its randomized, head-to-head phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo). The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or…
New optoretinography technique allows direct measurement of rod function in vivo | Ophthalmology Times
(Image Credit: AdobeStock/neosiam) A press release from the University of Washington, Seattle, reported what they described as a future diagnostic tool to view how the ocular molecules work. “Researchers have validated an approach to measure how rod photoreceptors, the cells…
iOpeners with Nicole Bajic, MD: Mary Qiu, MD, on tailored NVG pathways | Ophthalmology Times
With January being Glaucoma Awareness Month, it seems fitting to discuss neovascular glaucoma (NVG), a challenging and vision-threatening condition that requires thoughtful, individualized management. In this episode of iOpeners from Ophthalmology Times, host Nicole Bajic, MD, comprehensive ophthalmologist at the…
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA | Ophthalmology Times
Outlook Therapeutics, Inc. reported that the FDA has issued a complete response letter (CRL) concerning the resubmitted biologics license application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg).1,2 The letter noted that the agency cannot approve the application in its current form for the…
What changed in glaucoma care in 2025: Surgeon perspective | Ophthalmology Times
In a year-end conversation, Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas, in Dallas, sat down with the Eye Care Network to reflect on how glaucoma care evolved as 2025 drew to a close. Framing the discussion as a…
Comparing Aflibercept 8 mg and Faricimab in RVO | Ophthalmology Times
In this segment, the panel compares the pivotal QUASAR trial of aflibercept 8 mg in retinal vein occlusion (RVO) with the BALATON and COMINO trials evaluating faricimab. They note that all three studies demonstrated robust visual and anatomic improvements—typically gains…
Insights from Privotal Trials for Aflibercept (8 mg) in RVO | Ophthalmology Times
This segment explores emerging data on aflibercept 8 mg for retinal vein occlusion (RVO) and the evolving understanding of disease chronicity under anti-VEGF therapy. The panelists discuss the pivotal QUASAR trial, which uniquely combined CRVO and BRVO populations and demonstrated…
FDA approvals in 2025: What changed and why it matters for ophthalmologists | Ophthalmology Times
Editor’s Note: This content was generated with the assistance of AI. From first-in-class pharmacologic therapies to next-generation retinal durability strategies and less invasive surgical platforms, 2025 emerged as a pivotal year for the ophthalmic pipeline. Over the past 12 months,…
PRIMAvera study: Central vision improvement with subretinal implant | Ophthalmology Times
The implant is shown placed subretinally in an eye with geographic atrophy due to age-related macular degeneration. (Image courtesy of Frank G. Holz, MD, FEBO, FARVO) (PRIMA) system implant restored central vision and led to a significant improvement in visual…